Monte Rosa Therapeutics (NASDAQ:GLUE) versus Y-mAbs Therapeutics (NASDAQ:YMAB) Financial Analysis

Monte Rosa Therapeutics (NASDAQ:GLUE) and Y-mAbs Therapeutics (NASDAQ:YMAB) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.

Analyst Ratings

This is a summary of current ratings for Monte Rosa Therapeutics and Y-mAbs Therapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Monte Rosa Therapeutics	0	1	2	0	2.67
Y-mAbs Therapeutics	2	8	0	0	1.80

Monte Rosa Therapeutics presently has a consensus price target of $15.33, indicating a potential upside of 134.81%. Y-mAbs Therapeutics has a consensus price target of $9.62, indicating a potential upside of 11.76%. Given Monte Rosa Therapeutics’ stronger consensus rating and higher possible upside, equities analysts clearly believe Monte Rosa Therapeutics is more favorable than Y-mAbs Therapeutics.

Risk & Volatility

Monte Rosa Therapeutics has a beta of 1.42, suggesting that its share price is 42% more volatile than the S&P 500. Comparatively, Y-mAbs Therapeutics has a beta of 0.54, suggesting that its share price is 46% less volatile than the S&P 500.

Institutional & Insider Ownership

80.0% of Monte Rosa Therapeutics shares are held by institutional investors. Comparatively, 70.9% of Y-mAbs Therapeutics shares are held by institutional investors. 6.5% of Monte Rosa Therapeutics shares are held by company insiders. Comparatively, 19.7% of Y-mAbs Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Monte Rosa Therapeutics and Y-mAbs Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Monte Rosa Therapeutics	13.58%	9.95%	6.42%
Y-mAbs Therapeutics	-26.03%	-24.60%	-18.89%

Valuation & Earnings

This table compares Monte Rosa Therapeutics and Y-mAbs Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Monte Rosa Therapeutics	$75.62 million	5.33	-$72.70 million	$0.36	18.14
Y-mAbs Therapeutics	$87.68 million	4.46	-$29.67 million	($0.50)	-17.22

Y-mAbs Therapeutics has higher revenue and earnings than Monte Rosa Therapeutics. Y-mAbs Therapeutics is trading at a lower price-to-earnings ratio than Monte Rosa Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Monte Rosa Therapeutics beats Y-mAbs Therapeutics on 11 of the 14 factors compared between the two stocks.

About Monte Rosa Therapeutics

Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.